Zydus Lifesciences Limited

Symbol: ZYDUSLIFE.NS

NSE

981.35

INR

Market price today

  • 32.9550

    P/E Ratio

  • -2.1529

    PEG Ratio

  • 987.46B

    MRK Cap

  • 0.01%

    DIV Yield

Zydus Lifesciences Limited (ZYDUSLIFE-NS) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.66%

Operating Profit Margin

0.24%

Net Profit Margin

0.16%

Return on Assets

0.00%

Return on Equity

0.15%

Return on Capital Employed

0.00%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Punit Patel
Full-time employees:23026
City:Ahmedabad
Address:Zydus Corporate Park
IPO:2002-07-01
CIK:

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

General Outlook

When we look at how much money they make before expenses, they keep 0.659% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.239%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.161%. This tells us they're good at keeping money after all costs.

Return on Investments

Zydus Lifesciences Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.155%.

Stock Prices

Zydus Lifesciences Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1031.7, while its low point bottomed out at $996.5. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Zydus Lifesciences Limited's stock market.

Profitability Ratios

ZYDUSLIFE.NS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 20.25% underscores its earnings before tax deductions. The effective tax rate stands at 21.17%, revealing its tax efficiency. The net income per EBT, 79.35%, and the EBT per EBIT, 84.62%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 23.93%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin20.25%
Effective Tax Rate21.17%
Net Income per EBT79.35%
EBT per EBIT84.62%
EBIT per Revenue23.93%

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 14.57, and free cash flow per share, 14.57, depict cash generation on a per-share basis. The cash per share value, 15.01, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.08, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share14.57
Free Cash Flow per Share14.57
Cash per Share15.01
Operating Cash Flow Sales Ratio0.08
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of 59.60 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Interest Coverage59.60

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 13.83%, indicates top-line expansion, while the gross profit growth, 17.31%, reveals profitability trends. EBIT growth, 15.31%, and operating income growth, 15.31%, offer insights into operational profitability progression. The net income growth, -56.31%, showcases bottom-line expansion, and the EPS growth, 9.35%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth13.83%
Gross Profit Growth17.31%
EBIT Growth15.31%
Operating Income Growth15.31%
Net Income Growth-56.31%
EPS Growth9.35%
EPS Diluted Growth9.35%
Weighted Average Shares Growth-0.79%
Weighted Average Shares Diluted Growth-0.79%
Dividends per Share Growth-27.67%
Operating Cash Flow Growth27.79%
Free Cash Flow Growth83.90%
10-Year Revenue Growth per Share167.59%
5-Year Revenue Growth per Share46.67%
3-Year Revenue Growth per Share23.17%
10-Year Operating CF Growth per Share358.66%
5-Year Operating CF Growth per Share194.81%
3-Year Operating CF Growth per Share8.18%
10-Year Net Income Growth per Share202.36%
5-Year Net Income Growth per Share11.27%
3-Year Net Income Growth per Share67.93%
10-Year Shareholders Equity Growth per Share499.60%
5-Year Shareholders Equity Growth per Share101.90%
3-Year Shareholders Equity Growth per Share70.16%
10-Year Dividend per Share Growth per Share76.77%
3-Year Dividend per Share Growth per Share-62.33%
Receivables Growth-12.06%
Inventory Growth-8.23%
Asset Growth-7.34%
Book Value per Share Growth3.86%
Debt Growth-71.69%
R&D Expense Growth18.50%
SGA Expenses Growth18.80%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.68, and the price to book ratio, 4.68, reflect the market's valuation relative to the company's book value. The price to sales ratio, 5.26, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 66.06, and price to operating cash flows, 66.45, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio4.68
Price to Book Ratio4.68
Price to Sales Ratio5.26
Price Cash Flow Ratio66.45
Price Earnings to Growth Ratio-2.15
Enterprise Value Multiple18.53
Price Fair Value4.68
Price to Operating Cash Flow Ratio66.45
Price to Free Cash Flows Ratio66.06
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Zydus Lifesciences Limited (ZYDUSLIFE.NS) on the NSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 32.955 in 2024.

What is the ticker symbol of Zydus Lifesciences Limited stock?

The ticker symbol of Zydus Lifesciences Limited stock is ZYDUSLIFE.NS.

What is company IPO date?

IPO date of Zydus Lifesciences Limited is 2002-07-01.

What is company current share price?

Current share price is 981.350 INR.

What is stock market cap today?

The market cap of stock today is 987463810500.000.

What is PEG ratio in 2024?

The current -2.153 is -2.153 in 2024.

What is the number of employees in 2024?

In 2024 the company has 23026.